Company intelligence / Profile preview
Akava Therapeutics
Evanston, Illinois, United Statesakavatx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AKV9 has completed a Phase I clinical trial successfully under compassionate use and is now proceeding with a first-in-human Phase I study after FDA IND clearance. Preclinical studies demonstrated that AKV9 improves neuronal health by inhibiting protein aggregation and restoring cellular integrity in ALS mouse models. It shows additive effects when combined with existing ALS drugs riluzole or edaravone[1][4][5][9]. The drug targets multiple cellular degeneration pathways critical to disease progression.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecule therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Akava Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akava Therapeutics.